{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:17:57Z","timestamp":1787318277121,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4690,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1093\/annonc\/mdl395","type":"journal-article","created":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T20:40:09Z","timestamp":1162240809000},"page":"370-375","source":"Crossref","is-referenced-by-count":39,"title":["Phase II study of gemcitabine\u2013dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"F.","family":"Morschhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Depil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wetterwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Marit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Solal-C\u00e9ligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sebban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chouaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dumontet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl395_bb0010","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdl395_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0020","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"13","author":"Teodorovic","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl395_bb0030","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0035","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1023\/A:1008376728894","article-title":"Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma","volume":"10","author":"Lazzarino","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0045","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl395_bb0050","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cncr.10240","article-title":"Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma","volume":"94","author":"Seymour","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl395_bb0055","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/14656566.2.6.929","article-title":"Nucleoside analogues in the treatment of haematological malignancies","volume":"2","author":"Johnson","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1093\/annonc\/mdl395_bb0060","first-page":"16","article-title":"Preclinical combination therapy with gemcitabine and mechanisms of resistance","volume":"23","author":"Peters","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0065","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0070","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0075","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0080","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.1999.17.12.3786","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"17","author":"Fossa","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/01.coc.0000143015.66143.22","article-title":"A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma","volume":"28","author":"Larson","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0090","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdl395_bb0095","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1023\/A:1008307528519","article-title":"Gemcitabine for relapsed or resistant lymphoma","volume":"11","author":"Savage","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0100","first-page":"v131","article-title":"ESHAP chemotherapy regimen and 13-CIS-retinoic acid in elderly patients with untreated poor-prognosis peripheral T cell lymphoma: a GELA phase II trial of feasibility and efficacy","volume":"16","author":"Bouabdallah","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0105","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdl395_bb0115","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","article-title":"Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","volume":"101","author":"Crump","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl395_bb0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","article-title":"Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma","volume":"5","author":"Emmanouilides","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdl395_bb0125","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.bjc.6602514","article-title":"Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma","volume":"92","author":"Ng","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl395_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10428190400007540","article-title":"Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?","volume":"46","author":"Wenger","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdl395_bb0135","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl395_bb0145","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-03-0494","article-title":"Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors","volume":"10","author":"Zheng","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/2\/370\/696485\/mdl395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T04:25:51Z","timestamp":1624422351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419376136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0923753419376136"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl395","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}